GlobeNewswire (Thu, 1:44PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 22, 2013)
-
GlobeNewswire (Apr 17, 2013)
-
GlobeNewswire (Apr 12, 2013)
-
GlobeNewswire (Apr 2, 2013)
-
-
-
GlobeNewswire (Mar 8, 2013)
-
GlobeNewswire (Mar 5, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 13, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
IPO Preview: Durata TherapeuticsIPOdesktop • Wed, Jul 18, 2012
-
-
-
-
-
5 Low-Debt Biotech Stocks Forecasted For GrowthZetaKap • Sat, Sep 22, 2012 -
-
-
-
-
-
-
-
-
5 IPOs Planned For This WeekRenaissance Capital IPO Research • Tue, Jul 17, 2012
-
GlobeNewswire (Thu, 1:44PM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 22, 2013)
-
GlobeNewswire (Apr 17, 2013)
-
GlobeNewswire (Apr 12, 2013)
-
GlobeNewswire (Apr 2, 2013)
-
GlobeNewswire (Mar 8, 2013)
-
GlobeNewswire (Mar 5, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 13, 2013)
-
GlobeNewswire (Jan 4, 2013)
-
Business Wire (Dec 11, 2012)
-
Business Wire (Nov 14, 2012)
DRTX vs. ETF Alternatives
Company Description
We are a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with our lead product candidate, dalbavancin, for... More
